Alixia Therapeutics

Dania Therapeutics

The company develops small-molecule therapies targeting cancer metabolism to treat acute myeloid leukaemia and other life-threatening cancers for medical patients.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

AdoRx Therapeutics

This company develops small-molecule adenosine receptor antagonists for pharmaceutical partners to treat cancer by disrupting immune evasion in the tumour microenvironment.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

Lycia Therapeutics

The company develops extracellular protein-degrading therapeutics for patients with autoimmune, inflammatory and allergic diseases.